Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Directed Treatment in Metastatic Colorectal Cancer
NCT01703390Phase 2Completed
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
- Start
- Dec 2012
- Primary completion
- Feb 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Started Dec 2012; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01703390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01703390.